MX2023007405A - Regimen de cladribina para usarse en el tratamiento de formas progresivas de esclerosis multiple. - Google Patents
Regimen de cladribina para usarse en el tratamiento de formas progresivas de esclerosis multiple.Info
- Publication number
- MX2023007405A MX2023007405A MX2023007405A MX2023007405A MX2023007405A MX 2023007405 A MX2023007405 A MX 2023007405A MX 2023007405 A MX2023007405 A MX 2023007405A MX 2023007405 A MX2023007405 A MX 2023007405A MX 2023007405 A MX2023007405 A MX 2023007405A
- Authority
- MX
- Mexico
- Prior art keywords
- multiple sclerosis
- progressive forms
- cladribine
- progressive
- intreating
- Prior art date
Links
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 title abstract 2
- 229960002436 cladribine Drugs 0.000 title abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 230000000750 progressive effect Effects 0.000 title abstract 2
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 abstract 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona con el uso de dosificaciones orales específicas, formas de dosificación oral específicas y/o regímenes de dosis orales específicas que comprenden cladribina para el tratamiento de formas progresivas de esclerosis múltiple, especialmente esclerosis múltiple primaria progresiva y/o esclerosis múltiple secundaria progresiva, y métodos de tratamiento basados en la misma.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762590442P | 2017-11-24 | 2017-11-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007405A true MX2023007405A (es) | 2023-06-29 |
Family
ID=64457023
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005266A MX2020005266A (es) | 2017-11-24 | 2018-11-23 | Regimen de cladribina para usarse en el tratamiento de formas progresivas de esclerosis multiple. |
| MX2023007405A MX2023007405A (es) | 2017-11-24 | 2020-07-13 | Regimen de cladribina para usarse en el tratamiento de formas progresivas de esclerosis multiple. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005266A MX2020005266A (es) | 2017-11-24 | 2018-11-23 | Regimen de cladribina para usarse en el tratamiento de formas progresivas de esclerosis multiple. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10849919B2 (es) |
| EP (1) | EP3713582A1 (es) |
| JP (1) | JP2021504363A (es) |
| KR (1) | KR20200090824A (es) |
| CN (1) | CN111356460A (es) |
| AR (1) | AR113906A1 (es) |
| AU (1) | AU2018372007A1 (es) |
| BR (1) | BR112020010282A2 (es) |
| CA (1) | CA3083328A1 (es) |
| EA (1) | EA202091253A1 (es) |
| IL (1) | IL274777A (es) |
| MX (2) | MX2020005266A (es) |
| SG (1) | SG11202004772RA (es) |
| TW (1) | TW201936199A (es) |
| WO (1) | WO2019101960A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023002843A (es) * | 2020-09-10 | 2023-03-31 | Merck Patent Gmbh | Nuevo regimen de tratamiento para el tratamiento de trastornos autoinmunitarios. |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
| US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5641757A (en) | 1994-12-21 | 1997-06-24 | Ortho Pharmaceutical Corporation | Stable 2-chloro-2'-deoxyadenosine formulations |
| PL321431A1 (en) | 1994-12-22 | 1997-12-08 | Ortho Pharma Corp | Soluble 2-chloro-2'deoxyadenosine compositions |
| US6194395B1 (en) | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| WO2000064918A1 (en) | 1999-04-28 | 2000-11-02 | Sterrenbeld Biotechnologie North America, Inc. | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE |
| US7572909B2 (en) | 2002-09-25 | 2009-08-11 | Brigham Young University | Method for the preparation of 2-halo-2′-deoxyadenosine compounds from 2′-deoxyguanosine |
| EA009714B1 (ru) | 2003-03-28 | 2008-02-28 | Арес Трейдинг С.А. | Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки |
| RS20050735A (en) | 2003-03-28 | 2008-06-05 | Ares Trading S.A., | Cladribine formulations for improved oral and transmucosal delivery |
| EP2275110B1 (en) * | 2004-12-22 | 2013-07-10 | Merck Serono SA | Cladribine regimen for treating Multiple Sclerosis |
| CA2649810A1 (en) * | 2006-05-24 | 2007-11-29 | Laboratoires Serono S.A. | Cladribine regimen for treating multiple sclerosis |
| WO2017035357A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
-
2018
- 2018-11-23 JP JP2020528327A patent/JP2021504363A/ja active Pending
- 2018-11-23 AU AU2018372007A patent/AU2018372007A1/en active Pending
- 2018-11-23 TW TW107141805A patent/TW201936199A/zh unknown
- 2018-11-23 MX MX2020005266A patent/MX2020005266A/es unknown
- 2018-11-23 WO PCT/EP2018/082434 patent/WO2019101960A1/en unknown
- 2018-11-23 EA EA202091253A patent/EA202091253A1/ru unknown
- 2018-11-23 EP EP18808004.8A patent/EP3713582A1/en active Pending
- 2018-11-23 BR BR112020010282-2A patent/BR112020010282A2/pt unknown
- 2018-11-23 CA CA3083328A patent/CA3083328A1/en active Pending
- 2018-11-23 US US16/199,119 patent/US10849919B2/en active Active
- 2018-11-23 SG SG11202004772RA patent/SG11202004772RA/en unknown
- 2018-11-23 KR KR1020207017364A patent/KR20200090824A/ko not_active Application Discontinuation
- 2018-11-23 AR ARP180103432A patent/AR113906A1/es unknown
- 2018-11-23 CN CN201880075672.5A patent/CN111356460A/zh active Pending
-
2020
- 2020-05-19 IL IL274777A patent/IL274777A/en unknown
- 2020-07-13 MX MX2023007405A patent/MX2023007405A/es unknown
- 2020-10-23 US US16/949,278 patent/US20210169912A1/en active Pending
-
2022
- 2022-09-16 US US17/932,796 patent/US20230021880A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3713582A1 (en) | 2020-09-30 |
| MX2020005266A (es) | 2020-09-18 |
| WO2019101960A1 (en) | 2019-05-31 |
| EA202091253A1 (ru) | 2020-09-29 |
| US10849919B2 (en) | 2020-12-01 |
| US20210169912A1 (en) | 2021-06-10 |
| US20230021880A1 (en) | 2023-01-26 |
| JP2021504363A (ja) | 2021-02-15 |
| CA3083328A1 (en) | 2019-05-31 |
| AU2018372007A1 (en) | 2020-07-09 |
| AR113906A1 (es) | 2020-06-24 |
| CN111356460A (zh) | 2020-06-30 |
| KR20200090824A (ko) | 2020-07-29 |
| TW201936199A (zh) | 2019-09-16 |
| US20190167707A1 (en) | 2019-06-06 |
| IL274777A (en) | 2020-07-30 |
| SG11202004772RA (en) | 2020-06-29 |
| BR112020010282A2 (pt) | 2020-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY187540A (en) | Compounds active towards bromodomains | |
| MY192927A (en) | Fused bicyclic compounds for the treatment of disease | |
| FI3936130T3 (fi) | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| MX2021007773A (es) | Compuestos inhibidores de egfr. | |
| MX2017014191A (es) | Metodos de tratamiento de una enfermedad neurodegenerativa. | |
| PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
| MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
| MX2017008456A (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades. | |
| MA39803A (fr) | Anticorps hémagglutinine dirigés contre le virus de la grippe b et méthodes d'utilisation | |
| MX2017009047A (es) | Regimen de dosificacion para antagonistas de madcam. | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| IL268007A (en) | Anti-TNF antibodies, preparations and methods for the treatment of active psoriatic arthritis | |
| MX2017003216A (es) | Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. | |
| IL278889A (en) | Dosing regimen for the treatment of PI3K-related disorders | |
| IL272934A (en) | Pharmaceutical compositions containing a high dose of pridopidine | |
| MX2017014436A (es) | Compuestos biciclicos. | |
| MX370897B (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades,. | |
| MX2017014396A (es) | Tratamiento de mieloma multiple. | |
| MX2023007405A (es) | Regimen de cladribina para usarse en el tratamiento de formas progresivas de esclerosis multiple. | |
| MX2018014034A (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. | |
| MX2019014090A (es) | Métodos para el tratamiento de la reservoritis crónica. | |
| PH12017501897A1 (en) | 2-thiopyrimidinones | |
| JOP20200104A1 (ar) | مركبات مثبطة لـ btk | |
| JOP20200126A1 (ar) | طرق استخدام وتركيبات تحتوي على دولاجلوتيد |